Eli Lilly (LLY)
1,098.57
-13.43 (-1.21%)
NYSE· Last Trade: Jun 20th, 5:44 PM EDT
Detailed Quote
| Previous Close | 1,112.00 |
|---|---|
| Open | 1,120.49 |
| Bid | 1,098.99 |
| Ask | 1,103.99 |
| Day's Range | 1,088.65 - 1,122.33 |
| 52 Week Range | 623.78 - 1,182.73 |
| Volume | 4,470,563 |
| Market Cap | 1.05T |
| PE Ratio (TTM) | 47.87 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.63%) |
| 1 Month Average Volume | 3,280,924 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.
Via The Motley Fool · June 20, 2026
Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.
Via The Motley Fool · June 20, 2026
Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.
Via The Motley Fool · June 20, 2026
Eli Lilly & Co (NYSE:LLY): A Dividend Growth Gem with Strong Fundamentalschartmill.com
Via Chartmill · June 19, 2026
Eli Lilly & Co. (NYSE:LLY): High Growth Momentum Meets Strong Technical Breakout Setupchartmill.com
Via Chartmill · June 16, 2026
These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside
Via MarketBeat · June 20, 2026
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.
Via MarketBeat · June 20, 2026
Despite several setbacks over the past year, the drugmaker marches on.
Via The Motley Fool · June 20, 2026
These companies don't typically compete directly with one another, but that might change soon.
Via The Motley Fool · June 20, 2026
Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 12.92% on an annualized basis producing an average annual ...
Via Benzinga · June 19, 2026
AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience.
Via The Motley Fool · June 19, 2026
The iShares U.S. Healthcare ETF (IYH) tracks a broad healthcare index, while the Simplify Health Care ETF (PINK) gives an active manager more room to choose. That difference matters for investors deciding whether they want benchmark exposure or a more concentrated healthcare portfolio.
Via The Motley Fool · June 18, 2026
After a few days of purging, the Ark Invest growth investor is buying stocks again.
Via The Motley Fool · June 18, 2026
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.
Via MarketBeat · June 18, 2026
Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals.
Via The Motley Fool · June 18, 2026
Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability.
Via The Motley Fool · June 17, 2026
These stocks may not be your first choices when looking for dividends, but they have been income-generating machines for years.
Via The Motley Fool · June 17, 2026
These two healthcare leaders have a long history of competing against one another.
Via The Motley Fool · June 16, 2026
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.
Via The Motley Fool · June 16, 2026
Portfolio size and stock selection set these healthcare ETFs apart and help shape their risk and return profiles.
Via The Motley Fool · June 16, 2026
All three could become highly prominent biotech companies within 10 years.
Via The Motley Fool · June 16, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via StockStory · June 16, 2026
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
Via The Motley Fool · June 15, 2026
Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.
Via The Motley Fool · June 15, 2026
Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.
Via Benzinga · June 15, 2026